Product Introduction :
Favipiravir is a drug with a new mechanism, a broad-spectrum anti-influenza drug belonging to the RNA-dependent RNA polymerase (RdRP) inhibitor class, which was launched in Japan in 2014 , Used to treat new and recurrent influenza, and become Japan's national strategic reserve drug.
Favilavir is a pyrazinamide derivative, which has the effect of reducing the activity of influenza virus, West Nile virus, yellow fever, foot-and-mouth disease virus and many other viruses. It has also been shown to inhibit activities such as enterovirus and Rift Valley fever. .
In China, favilavir has been approved for clinical trials for the treatment of COVID - 19 infection. The results of the study show that favilavir has initially shown more obvious efficacy and lower adverse reactions in the treatment of new coronary pneumonia.
Indications :
For the treatment of new or re-epidemic influenza in adults (only used when other antiviral drugs are ineffective or ineffective)
Administration and Dosage :
Oral administration on an empty stomach
After the flu symptoms are discovered, the drug is administered quickly, and the course of treatment for adults usually lasts for 5 days.
On day 1, 1600 mg each time, 2 times a day; from day 2 to day 5, 600 mg each time, 2 times a day.
